1.00 / 3.39 %
41.24 %
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 27 2016 10:59 BST.
IMM:LSE is traded on the London Stock Exchange Alternative Investment Market (Aim)


On Friday, ImmuPharma PLC (IMM:LSE) closed at 28.50, 49.21% above the 52 week low of 19.10 set on Dec 04, 2015.

52-week range
Dec 04 2015
Jun 16 2015
Day high29.37
Day low29.00
Previous close29.50
Average volume392.76k
Shares outstanding121.78m
Free float71.68m
P/E (TTM)--
Market cap34.71m GBP
EPS (TTM)-0.044 GBP
Data delayed at least 15 minutes, as of May 27 2016 10:59 BST.

RNS Company announcements

Result of AGM
Holding(s) in Company
Annual Financial Report & Notice of AGM
Final Results
Notice of Results

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
ImmuPharma PLC+5.56 %-6.56 %+25.27 %-41.24 %-65.45 %
FTSE 100 IDX+1.86 %-0.78 %-1.64 %-10.84 %+5.59 %
GB/HEALTH CARE+1.75 %-0.27 %-2.43 %-9.18 %+22.65 %
GB/PHARMACEUTICALS+1.68 %-0.26 %-2.85 %-9.77 %+21.28 %
Data delayed at least 15 minutes, as of May 27 2016 10:59 BST.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.